[
  {
    "ts": null,
    "headline": "Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC",
    "summary": "Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, highlighting significant benefits in treating metastatic triple-negative breast cancer. This development may have supported the company's 12% price gain in the last quarter, complementing broader oncology advances. Despite a turbulent broader market impacted by global trade tension and inflationary pressures, Gilead's progress in clinical research, financial performance, and...",
    "url": "https://finnhub.io/api/news?id=9a0359fe0ca839c5331dab00f738139437508fa12a740a188f18288dba623b13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745255695,
      "headline": "Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC",
      "id": 134026441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, highlighting significant benefits in treating metastatic triple-negative breast cancer. This development may have supported the company's 12% price gain in the last quarter, complementing broader oncology advances. Despite a turbulent broader market impacted by global trade tension and inflationary pressures, Gilead's progress in clinical research, financial performance, and...",
      "url": "https://finnhub.io/api/news?id=9a0359fe0ca839c5331dab00f738139437508fa12a740a188f18288dba623b13"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finnhub.io/api/news?id=65a44e31c47c8708a5a866ea6d6338ed15c4055f7c330ef3c0d96b1bd2fdf09c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745240408,
      "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "id": 134022887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
      "url": "https://finnhub.io/api/news?id=65a44e31c47c8708a5a866ea6d6338ed15c4055f7c330ef3c0d96b1bd2fdf09c"
    }
  },
  {
    "ts": null,
    "headline": "Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer",
    "summary": "FOSTER CITY, Calif., April 21, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS ≥ 10). The st",
    "url": "https://finnhub.io/api/news?id=c5090489ca1699116b8e5a0818abcce9d0748d460c61eedec62cd763a9f3351d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745238600,
      "headline": "Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer",
      "id": 134022888,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., April 21, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS ≥ 10). The st",
      "url": "https://finnhub.io/api/news?id=c5090489ca1699116b8e5a0818abcce9d0748d460c61eedec62cd763a9f3351d"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Sees Positive Results in Phase 3 Study of Aggressive Breast Cancer",
    "summary": "By Sabela Ojea Gilead Sciences said that it saw positive results from the phase 3 study of its Trodelvy therapy in combination with Merck's Keytruda in patients with inoperable locally advanced...",
    "url": "https://finnhub.io/api/news?id=ab859a8d3f44edfb0b5eae9e284e8167bdbe92c9adf521859d60c87952a85872",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745227808,
      "headline": "Gilead Sciences Sees Positive Results in Phase 3 Study of Aggressive Breast Cancer",
      "id": 134022018,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "By Sabela Ojea Gilead Sciences said that it saw positive results from the phase 3 study of its Trodelvy therapy in combination with Merck's Keytruda in patients with inoperable locally advanced...",
      "url": "https://finnhub.io/api/news?id=ab859a8d3f44edfb0b5eae9e284e8167bdbe92c9adf521859d60c87952a85872"
    }
  }
]